Package Leaflet: Information for the User
Rivaroxaban TAD 15 mg film-coated tablets EFG
Rivaroxaban TAD 20 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Rivaroxaban TAD contains the active substance rivaroxaban. It is used in adults to:
Rivaroxaban TAD is used in children and adolescents under 18 years of age and with a body weight of 30 kg or more to:
This medicine belongs to a group of medicines called antithrombotic agents. It works by blocking a factor in the blood that is involved in blood clotting (factor Xa) and thus reduces the tendency of the blood to form clots.
Do not take Rivaroxaban TAD
Do not take this medicine and inform your doctorif any of these apply to you.
Warnings and precautions
Talk to your doctor or pharmacist before taking this medicine.
Be careful with Rivaroxaban TAD
Tell your doctor if you have any of these conditionsbefore taking this medicine. Your doctor will decide if you should be treated with this medicine and if you should be kept under closer observation.
If you need to have surgery
Children and adolescents
This medicine is not recommended in children with a body weight below 30 kg.There is not enough information about its use in children and adolescents.
Other medicines and this medicine
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including those obtained without a prescription.
If any of the above applies to you, tell your doctorbefore taking this medicine, as the effect of this medicine may be increased. Your doctor will decide if you should be treated with this medicine and if you should be kept under closer observation.
If your doctor thinks you have a higher risk of developing a stomach or intestinal ulcer, they may recommend that you also take a preventative treatment.
If any of the above applies to you, tell your doctorbefore taking rivaroxaban, as the effect of this medicine may be reduced. Your doctor will decide if you should be treated with this medicine and if you should be kept under closer observation.
Pregnancy, breastfeeding and fertility
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Do not take this medicine if you are pregnant or breastfeeding. If you could become pregnant, use a reliable contraceptive while taking this medicine. If you become pregnant while taking this medicine, tell your doctor immediately, who will decide how you should be treated.
Driving and using machines
This medicine may cause dizziness (common side effect) or fainting (uncommon side effect) (see section 4 "Possible side effects"). Do not drive, ride a bicycle or use tools or machines if you are affected by these symptoms.
Rivaroxaban TAD contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
You should take this medicine with food.
Swallow the tablets with water, preferably with water.
If you have difficulty swallowing the tablet whole, ask your doctor about other ways to take this medicine. The tablet can be crushed and mixed with water or apple sauce, immediately before taking it. If necessary, your doctor may also administer the crushed rivaroxaban tablet through a gastric tube.
What dose to take
The recommended dose is one 20 mg tablet once a day.
If you have kidney problems, the dose may be reduced to one 15 mg tablet once a day.
If you need to undergo a procedure to treat blocked blood vessels in your heart (called percutaneous coronary intervention - PCI with stent insertion), there is limited evidence to reduce the dose to one 15 mg rivaroxaban tablet once a day (or one 10 mg rivaroxaban tablet once a day if your kidneys do not work properly) in addition to an antiplatelet medicine such as clopidogrel.
The recommended dose is one 15 mg tablet twice a day for the first 3 weeks. For treatment after 3 weeks, the recommended dose is one 20 mg tablet once a day.
After at least 6 months of treatment for blood clots, your doctor may decide to continue treatment with one 10 mg tablet once a day or one 20 mg tablet once a day.
If you have kidney problems and are taking one 20 mg rivaroxaban tablet once a day, your doctor may decide to reduce the treatment dose to one 15 mg tablet once a day after 3 weeks if the risk of bleeding is higher than the risk of having another blood clot.
The dose of rivaroxaban depends on body weight and will be calculated by your doctor.
Take each dose of rivaroxaban with a drink (e.g. water or juice) during a meal. Take the tablets every day at approximately the same time. Consider setting an alarm to remind you.
For parents or caregivers: observe the child to ensure they take the entire dose.
Since the dose of rivaroxaban is based on body weight, it is important to attend scheduled visits with your doctor, as the dose may need to be adjusted as the weight changes.
Never adjust the dose of rivaroxaban on your own. Your doctor will adjust the dose if necessary.
Do not split the tablet to try to get a fraction of the tablet dose. If a smaller dose is required, please use the alternative rivaroxaban granules for oral suspension.
In children and adolescents who cannot swallow the tablets whole, please use rivaroxaban granules for oral suspension.
If the oral suspension is not available, you can crush the rivaroxaban tablet and mix it with water or apple sauce immediately before taking it. Take some food after taking this mixture. If necessary, your doctor may also administer the crushed rivaroxaban tablet through a gastric tube.
If you spit out the dose or vomit
Call your doctor if you spit out the dose or vomit repeatedly after taking rivaroxaban.
When to take Rivaroxaban TAD
Take the tablets every day, until your doctor tells you to stop.
Try to take the tablets at the same time every day to remember when to take them.
Your doctor will decide how long you should take this medicine.
To prevent blood clots in the brain (stroke) or in other blood vessels: If you need to have your heartbeat normalized through a procedure called cardioversion, take this medicine at the times your doctor has indicated.
If you forget to take Rivaroxaban TAD
If you are taking one 20 mg or one 15 mg tablet oncea day, and you miss a dose, take it as soon as you remember. Do not take more than one tablet in one day to make up for a missed dose. Take the next tablet the next day and then continue taking one tablet every day.
If you take more Rivaroxaban TAD than you should
Contact your doctor immediately if you have taken too many tablets of this medicine. Taking too much medicine increases the risk of bleeding.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.
If you stop taking Rivaroxaban TAD
Do not stop taking this medicine without first talking to your doctor, as this medicine treats and prevents serious conditions.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Like other similar medicines to reduce blood clot formation, this medicine can cause bleeding that can endanger the patient's life. Excessive bleeding can cause a sudden drop in blood pressure (shock). In some cases, the bleeding may not be evident.
Tell your doctor immediately if you or your child experience any of the following symptoms:
Signs of bleeding
Your doctor will decide whether to keep you under closer observation or change your treatment.
Signs of severe skin reaction
The frequency of these adverse effects is very rare (up to 1 in 10,000 people).
Signs of severe allergic reaction
The frequencies of severe allergic reactions are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic edema; may affect up to 1 in 100 people).
General list of possible adverse effects in adults, children, and adolescents
Frequent(may affect up to 1 in 10 patients)
Uncommon(may affect up to 1 in 100 patients)
Rare(may affect up to 1 in 1,000 patients)
Very rare(may affect up to 1 in 10,000 people)
Frequency not known(frequency cannot be estimated from available data)
Adverse effects in children and adolescents
In general, the adverse effects observed in children and adolescents treated with rivaroxaban were similar to those observed in adults and their severity was mainly mild to moderate.
Adverse effects that were more frequently observed in children and adolescents:
Very frequent(may affect more than 1 in 10 people)
Frequent(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Reporting of adverse effects
If you experience adverse effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging and on each blister after "EXP". The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in your pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Rivaroxaban TAD
15 mg: Each film-coated tablet contains 15 mg of rivaroxaban.
20 mg: Each film-coated tablet contains 20 mg of rivaroxaban.
Appearance of the product and package contents
15 mg:Film-coated tablets, orange-red to orange-brown in color, round, slightly biconvex, engraved with the mark "15" on one face of the tablet.
Dimensions: diameter of approximately 6.5 mm.
20 mg:Film-coated tablets, pink to dark pink in color, round, slightly biconvex, engraved with the mark "20" on one face of the tablet.
Dimensions: diameter of approximately 7 mm.
Rivaroxaban TAD is available in packs containing:
Non-perforated blister: 100 film-coated tablets.
Perforated unit-dose blister: 100 x 1 film-coated tablets.
Calendarized non-perforated blister: 14, 28, and 42 film-coated tablets.
The patient alert card is included in each pack of this medicine.
Only some pack sizes may be marketed.
Marketing authorization holder
TAD Pharma GmbH, Heinz-Lohmann Straße 5, 27472 Cuxhaven, Germany
Manufacturer
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
TAD Pharma GmbH, Heinz-Lohmann Straße 5, 27472 Cuxhaven, Germany
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
KRKA Farmacéutica, S.L., Calle de Anabel Segura 10, 28108 Alcobendas, Madrid, Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
Member State | Medicine name |
Denmark | Rivaroxaban TAD 15 mg filmovertrukne tabletter Rivaroxaban TAD 20 mg filmovertrukne tabletter |
Austria | Rivaroxaban HCS 15 mg Filmtabletten Rivaroxaban HCS 20 mg Filmtabletten |
Spain | Rivaroxaban TAD 15 mg comprimidos recubiertos con película EFG Rivaroxaban TAD 20 mg comprimidos recubiertos con película EFG |
Italy | Rivaroxaban Krka 15 mg Rivaroxaban Krka 20 mg |
Date of the last revision of this leaflet:February 2024
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/